UNSPSC 51372011: Levophenacylmorphan

This classification denotes an opioid receptor agonist with the molecular formula C24H27NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Q24AL2BR2, chemically known as morphinan-3-ol, 17-(2-oxo-2-phenylethyl)- but generally known as levophenacylmorphan, which bears US NIH Compound Identifier 517743. European Medicines Agency schedules Levophenacylmorphan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08484MIG.

UNSPSC 51372011 Levophenacylmorphan is a Commodity code that does not reflect the products state and local governments are actually procuring under this classification. The recent opportunities posted under this code involve naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription program infrastructure — none of which fall within the scope of levophenacylmorphan, a specific opioid analgesic compound. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating states). The work being solicited reflects pharmaceutical supply procurement, inventory management, and benefit program administration rather than the acquisition of a single active pharmaceutical ingredient.

The geographic spread of recent activity centers on Florida, Texas, and the Upper Midwest through cooperative purchasing mechanisms. Seminole County released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 to explore direct-to-manufacturer prescription program capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance released an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to provide comprehensive pricing through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC wholesalers. The code shows misalignment between its nominal pharmaceutical ingredient scope and actual state and local procurement activity, suggesting either a taxonomy classification error or that this code receives minimal relevant solicitation volume.